Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer
NCT04205071 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2021-01-19
Summary
This phase I trial studies how well lorcaserin works in treating chemotherapy-induced peripheral neuropathy in patients with stage I-IV gastrointestinal or breast cancer. Chemotherapy-induced peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. This condition can occur in patients who have received taxane chemotherapy drugs, or the chemotherapy drug oxaliplatin. Lorcaserin may improve chemotherapy-induced peripheral neuropathy by reducing pain, preventing or relieving joint symptoms, and improving balance.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Chemotherapy-Induced Peripheral Neuropathy
- Digestive System Carcinoma
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
Interventions
- DRUG
-
Lorcaserin
Given PO
- DRUG
-
Lorcaserin Hydrochloride
Given PO
- OTHER
-
Questionnaire Administration
Ancillary studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Ohio State University Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Maryam B Lustberg, MD · Ohio State University Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-01
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
- FDA Drug
- Yes
More Related Trials
-
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
NCT00635050 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
NCT01708798 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
NCT03872141 ·Status: COMPLETED
-
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894 ·Status: COMPLETED ·Phase: PHASE2
-
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00003032 ·Status: COMPLETED ·Phase: PHASE3
-
Docetaxel in Treating Older Women With Metastatic Breast Cancer
NCT00104624 ·Status: TERMINATED ·Phase: PHASE2
-
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
NCT00079118 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
NCT00067314 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00079170 ·Status: COMPLETED ·Phase: NA
-
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
NCT00378313 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
NCT01823835 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
NCT02360059 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
NCT00054275 ·Status: COMPLETED ·Phase: PHASE2
-
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
NCT02338115 ·Status: COMPLETED
-
Chemotherapy-Induced Peripheral Neuropathy Survey
NCT01016028 ·Status: WITHDRAWN
-
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
NCT00191438 ·Status: COMPLETED ·Phase: PHASE3
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer
NCT00214864 ·Status: COMPLETED ·Phase: PHASE2
-
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
NCT01982591 ·Status: COMPLETED
-
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
NCT00074139 ·Status: WITHDRAWN ·Phase: PHASE1
-
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
NCT01329627 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
NCT00004125 ·Status: COMPLETED ·Phase: PHASE3
-
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
NCT03568422 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00002627 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2